# Hardman & Co: Allergy Therapeutics plc

- Link: https://www.directorstalkinterviews.com/hardman-co-allergy-therapeutics-plc/412745054
- Published: 2018-02-02T10:47:26+00:00
- Author: Amilia Stone

**Growth in a tough market**

Allergy Therapeutics plc ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l))
is a long-established specialist in the prevention, diagnosis and treatment of allergies.
Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues
to gain market share despite being available in the EU only on a ‘Named Patient’
basis. Trials designed to obtain regulatory approval for PQ approved as a biologic
in both Europe and the US are well advanced. Meanwhile, although underlying sales
growth was weaker than expected in 1H’18, this was on the back of an unusually shorter
and lower pollen season in central Europe, suggesting that AGY has continued to 
make further market share gains.

► Strategy: AGY is a fully integrated pharmaceutical company focused on the treatment
of allergies. There are three parts to its strategy: continued development of its
European business via investment or opportunistic acquisitions; the US PQ opportunity;
and further development of its pipeline.

► Trading update: In 1H’18, underlying sales grew 1.3% to £42.2m (£40.4m), which
was about 10% below expectations, largely because of an unexpectedly weak pollen
season. Timing of R&D spend, coupled with careful control of costs and working capital,
generated a cash position of £25.8m (£27.8m).

► Pollen season: Reports show that the pollen season was very weak in 2017, particularly
in AGY’s key markets of central Europe, Germany, Austria and Switzerland. Therefore,
there is reason to believe that the low sales growth in 1H’18 was still sufficient
for AGY to make further market share gains.

► R&D spend: Clinical trials designed to get full regulatory approval of Pollinex
Quattro (PQ) as a biologic continue apace. The Phase III PQ Birch trial is fully
recruited, with results due to be released in 2H calendar 2018. The Phase II PQ 
grass trial is still recruiting. Timing of R&D spend does affect the cash position.

► Investment summary: AGY is going through an exciting period, with a clear vision,
gaining market share from competitors, and leading the race to have its products
fully approved and regulated as biologicals – first in Europe, then in the US, where
the regulators are demanding change. Read-out from the EU Phase III PQ Birch trial
in 2018 will provide the next major value inflection point.

 

[To read the full news article please click here](http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/02.02.18-growth-in-a-tough-market.pdf)

Share on:
